Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have received an average rating of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $32.00.

A number of equities research analysts have recently weighed in on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $36.00 target price on shares of Tyra Biosciences in a research note on Wednesday, September 10th. Wall Street Zen cut Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, August 22nd. Finally, Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Thursday, November 6th.

Tyra Biosciences Stock Up 0.6%

Shares of Tyra Biosciences stock opened at $22.03 on Friday. The business has a 50 day moving average of $15.24 and a 200 day moving average of $12.24. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $22.68. The company has a market cap of $1.18 billion, a PE ratio of -11.78 and a beta of 1.12.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). On average, research analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Activity at Tyra Biosciences

In other news, Director Robert J. More sold 246,871 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $20.25, for a total value of $4,999,137.75. Following the sale, the director directly owned 3,833,425 shares of the company’s stock, valued at $77,626,856.25. This represents a 6.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. grew its stake in shares of Tyra Biosciences by 23.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 301,801 shares of the company’s stock worth $2,807,000 after acquiring an additional 57,556 shares during the last quarter. Polar Asset Management Partners Inc. boosted its stake in Tyra Biosciences by 27.1% in the 1st quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company’s stock worth $1,314,000 after purchasing an additional 30,134 shares in the last quarter. Nuveen LLC bought a new position in Tyra Biosciences in the 1st quarter worth about $465,000. Public Employees Retirement System of Ohio purchased a new stake in Tyra Biosciences during the 2nd quarter valued at about $177,000. Finally, Corton Capital Inc. bought a new stake in Tyra Biosciences during the 2nd quarter valued at about $233,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.